Trials / Recruiting
RecruitingNCT07123909
Studies on Adsorption International Learning Initiative Global
The Use of Sorption Technologies in Patients Receiving Program Hemodialysis With Inflammatory Syndrome
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Botkin Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Use of sorption technologies in patients undergoing maintenance hemodialysis with inflammatory syndrome and clinical manifestations of uremia
Detailed description
This study will involve 30 hemodialysis patients selected based on examination results showing elevated C-reactive protein (CRP) and/or interleukin-6 (IL-6) levels. Participants will undergo hemoadsorption with the Jafron HA130 cartridge performed concurrently with hemodialysis: three times per week during the first month, twice per week during the second month, and once per week during the third month. The following parameters will be assessed: inflammatory markers (CRP, IL-1, IL-6, IL-8, β2-microglobulin, free light chains of immunoglobulins), parathyroid hormone (PTH), standard biochemical blood tests (creatinine, urea, calcium, phosphorus, albumin, iron metabolism), and complete blood count. Analyses will be performed at baseline (before inclusion) and monthly thereafter.
Conditions
- CKD (Chronic Kidney Disease) Stage 5D
- Uremia; Chronic
- Uremic; Toxemia
- Inflammation Chronic
- Hemodialysis
- Inflammation Biomarkers
- Dialysis Related Complication
- Anemia Associated With End Stage Renal Disease
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Patients will undergo a combined hemodialysis and hemosorption procedure. The study cartridge for hemosorption by Jafron HA130 contains the original adsorbing material. | The test cartridge will be used in addition to the ongoing program hemodialysis three times a week in the first month, twice a week in the next month, once a week in the third month |
Timeline
- Start date
- 2025-06-01
- Primary completion
- 2026-03-31
- Completion
- 2026-06-30
- First posted
- 2025-08-14
- Last updated
- 2025-12-10
Locations
1 site across 1 country: Russia
Source: ClinicalTrials.gov record NCT07123909. Inclusion in this directory is not an endorsement.